Status of hyperhomocysteinemia in China: results from the China Stroke High-risk Population Screening Program, 2018

doi:10.1007/s11684-021-0871-4

Front. Med.

2021, Vol. 15

Issue (6) : 903-912 https://doi.org/10.1007/s11684-021-0871-4

RESEARCH ARTICLE

Status of hyperhomocysteinemia in China: results from the China Stroke High-risk Population Screening Program, 2018

Wenjun Tu^1,^2,³, Feng Yan⁴, Baohua Chao², Xunming Ji⁴(

), Longde Wang²(

)

¹. Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China
². The General Office of Stroke Prevention Project Committee, National Health Commission of the People’s Republic of China, Beijing 100053, China
³. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
⁴. Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

Download: PDF(746 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

A nationwide survey was conducted from October 2018 to September 2019 to assess the prevalence of hyperhomocysteinemia (Hhcy) and its influencing factors in China. A standardized questionnaire was used to collect information. Hhcy was defined as the level of serum homocysteine (HCY) $≥$ 15.0 µmol/L. The H-type hypertension (HHYP) was defined as hypertension with an elevated serum HCY ( $≥$ 15.0 µmol/L). Finally, 110 551 residents $≥$ 40 years of age from 31 provinces in the mainland of China were included. Overall, the median serum HCY level was 10.9 µmol/L (interquartile range 7.9–15.1). A total of 28 633 participants (25.9%) were defined as Hhcy. The Hhcy prevalence ranged from 7.9% in Shanghai to 56.8% in Tianjin. The data showed that serum HCY levels were associated with age, male gender, cigarette smoking, hypertension, diabetes, ethnicity, endurance in exercise (inverse), and fruit and vegetable intake (inverse). In addition, 15 486 participants were defined as HHYP, and the rate was 14.0%. HHYP was an independent predictor of stroke with an adjusted odds ratio of 1.752 (95% CI 1.338–2.105). The geographical distribution pattern of the Hhcy epidemic reflects dynamic differences, and national strategies should be carried out to further improve the care of patients with Hhcy across China.

Keywords homocysteine hyperhomocysteinemia H-type hypertension Chinese

Corresponding Author(s): Xunming Ji,Longde Wang

Just Accepted Date: 16 November 2021 Online First Date: 09 December 2021 Issue Date: 27 December 2021

Cite this article:

Wenjun Tu,Feng Yan,Baohua Chao, et al. Status of hyperhomocysteinemia in China: results from the China Stroke High-risk Population Screening Program, 2018[J]. Front. Med., 2021, 15(6): 903-912.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-021-0871-4
https://academic.hep.com.cn/fmd/EN/Y2021/V15/I6/903

1	The GBD 2016 Lifetime Risk of Stroke Collaborators. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med 2018; 379: 2429–2437 https://doi.org/DOI: 10.1056/NEJMoa1804492 pmid: 30575491
2	S Wu, B Wu, M Liu, Z Chen, W Wang, CS Anderson, P Sandercock, Y Wang, Y Huang, L Cui, C Pu, J Jia, T Zhang, X Liu, S Zhang, P Xie, D Fan, X Ji, KL Wong, L Wang; China Stroke Study Collaboration. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol 2019; 18(4): 394–405 https://doi.org/10.1016/S1474-4422(18)30500-3 pmid: 30878104
3	W Wang, B Jiang, H Sun, X Ru, D Sun, L Wang, L Wang, Y Jiang, Y Li, Y Wang, Z Chen, S Wu, Y Zhang, D Wang, Y Wang, VL; NESS-China Investigators Feigin. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults. Circulation 2017; 135(8): 759–771 https://doi.org/10.1161/CIRCULATIONAHA.116.025250 pmid: 28052979
4	BH Chao, F Yan, Y Hua, JM Liu, Y Yang, XM Ji, B Peng, GG Zhao, YJ Wang, DZ Kang, YL Wang. Stroke prevention and control system in China: CSPPC-Stroke Program. Int J Stroke 2021; 16(3): 265–272 https://doi.org/10.1177/1747493020913557 pmid: 32223541
5	Z Wang, Z Chen, L Zhang, X Wang, G Hao, Z Zhang, L Shao, Y Tian, Y Dong, C Zheng, J Wang, M Zhu, WS Weintraub, R; hina Hypertension Survey Investigators Gao. Status of hypertension in China: results from the China hypertension survey, 2012–2015. Circulation 2018; 137(22): 2344–2356 https://doi.org/10.1161/CIRCULATIONAHA.117.032380 pmid: 29449338
6	J Lu, Y Lu, X Wang, X Li, GC Linderman, C Wu, X Cheng, L Mu, H Zhang, J Liu, M Su, H Zhao, ES Spatz, JA Spertus, FA Masoudi, HM Krumholz, L Jiang. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet 2017; 390(10112): 2549–2558 https://doi.org/10.1016/S0140-6736(17)32478-9 pmid: 29102084
7	L Zheng, Z Sun, J Li, R Zhang, X Zhang, S Liu, J Li, C Xu, D Hu, Y Sun. Pulse pressure and mean arterial pressure in relation to ischemic stroke among patients with uncontrolled hypertension in rural areas of China. Stroke 2008; 39(7): 1932–1937 https://doi.org/10.1161/STROKEAHA.107.510677 pmid: 18451345
8	JD Bundy, J He. Hypertension and related cardiovascular disease burden in China. Ann Glob Health 2016; 82(2): 227–233 https://doi.org/10.1016/j.aogh.2016.02.002 pmid: 27372527
9	GJ Hankey, JW Eikelboom. Homocysteine and vascular disease. Lancet 1999; 354(9176): 407–413 https://doi.org/10.1016/S0140-6736(98)11058-9 pmid: 10437885
10	Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288(16): 2015–2022 https://doi.org/10.1001/jama.288.16.2015 pmid: 12387654
11	J Selhub. Homocysteine metabolism. Annu Rev Nutr 1999; 19(1): 217–246 https://doi.org/10.1146/annurev.nutr.19.1.217 pmid: 10448523
12	H Refsum, PM Ueland, O Nygård, SE Vollset. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49(1): 31–62 https://doi.org/10.1146/annurev.med.49.1.31 pmid: 9509248
13	B Yang, S Fan, X Zhi, Y Wang, Y Wang, Q Zheng, G Sun. Prevalence of hyperhomocysteinemia in China: a systematic review and meta-analysis. Nutrients 2014; 7(1): 74–90 https://doi.org/10.3390/nu7010074 pmid: 25551247
14	Z Li, X Guo, S Chen, L Zheng, H Yang, G Sun, S Yu, W Li, L Zhou, J Wang, W Hu, Y Sun. Hyperhomocysteinemia independently associated with the risk of hypertension: a cross-sectional study from rural China. J Hum Hypertens 2016; 30(8): 508–512 https://doi.org/10.1038/jhh.2015.75 pmid: 26155996
15	IM van Beynum, JA Smeitink, M den Heijer, MT te Poele Pothoff, HJ Blom. Hyperhomocysteinemia: a risk factor for ischemic stroke in children. Circulation 1999; 99(16): 2070–2072 https://doi.org/10.1161/01.CIR.99.16.2070 pmid: 10217643
16	Y Zhang, Y Huo. Hypertension with elevated homocysteine—H-type hypertension. Adv Cardiovasc Dis 2011; 32: 3–6
17	DY Hu, XP Xu. Prevention of stroke relies on valid control “H” type hypertension. Chin J Intern Med (Zhonghua Nei Ke Za Zhi) 2008; 47(12): 976–977 (in Chinese) pmid: 19134296
18	Q Zhang, DX Qiu, RL Fu, TF Xu, MJ Jing, HS Zhang, HH Geng, LC Zheng, PX Wang. H-type hypertension and C reactive protein in recurrence of ischemic stroke. Int J Environ Res Public Health 2016; 13(5): 477 https://doi.org/10.3390/ijerph13050477 pmid: 27164124
19	T Guan, J Ma, M Li, T Xue, Z Lan, J Guo, Y Shen, B Chao, G Tian, Q Zhang, L Wang, Y Liu. Rapid transitions in the epidemiology of stroke and its risk factors in China from 2002 to 2013. Neurology 2017; 89(1): 53–61 https://doi.org/10.1212/WNL.0000000000004056 pmid: 28566547
20	DW Jacobsen. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998; 44(8): 1833–1843 https://doi.org/10.1093/clinchem/44.8.1833 pmid: 9702993
21	J Zhang, Y Liu, A Wang, D Wang, R Jiang, J Jia, S Chen, X Zhao. Association between H-type hypertension and asymptomatic extracranial artery stenosis. Sci Rep 2018; 8(1): 1328 https://doi.org/10.1038/s41598-018-19740-0 pmid: 29358636
22	M Cattaneo. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81(2): 165–176 https://doi.org/10.1055/s-0037-1614438 pmid: 10063987
23	DS Wald, M Law, JK Morris. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325(7374): 1202–1206 https://doi.org/10.1136/bmj.325.7374.1202 pmid: 12446535
24	H Pang, B Han, Q Fu, L Hao, Z Zong. Association between homocysteine and conventional predisposing factors on risk of stroke in patients with hypertension. Sci Rep 2018; 8(1): 3900 https://doi.org/10.1038/s41598-018-22260-6 pmid: 29497105
25	CY Wang, ZW Chen, T Zhang, J Liu, SH Chen, SY Liu, LY Han, ZH Hui, YM Chen. Elevated plasma homocysteine level is associated with ischemic stroke in Chinese hypertensive patients. Eur J Intern Med 2014; 25(6): 538–544 https://doi.org/10.1016/j.ejim.2014.04.011 pmid: 24824758
26	L Han, Q Wu, C Wang, Y Hao, J Zhao, L Zhang, R Fan, Y Liu, R Li, Z Chen, T Zhang, S Chen, J Ma, S Liu, X Peng, S Duan. Homocysteine, ischemic stroke, and coronary heart disease in hypertensive patients: a population-based, prospective cohort study. Stroke 2015; 46(7): 1777–1786 https://doi.org/10.1161/STROKEAHA.115.009111 pmid: 26038522
27	FM Faraci, SR Lentz. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke 2004; 35(2): 345–347 https://doi.org/10.1161/01.STR.0000115161.10646.67 pmid: 14757874
28	RC Austin, SR Lentz, GH Werstuck. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 2004; 11(Suppl 1): S56–S64 https://doi.org/10.1038/sj.cdd.4401451 pmid: 15243582
29	MA Hofmann, E Lalla, Y Lu, MR Gleason, BM Wolf, N Tanji, LJ Ferran Jr, B Kohl, V Rao, W Kisiel, DM Stern, AM Schmidt. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001; 107(6): 675–683 https://doi.org/10.1172/JCI10588 pmid: 11254667
30	E Lonn, S Yusuf, MJ Arnold, P Sheridan, J Pogue, M Micks, MJ McQueen, J Probstfield, G Fodor, C Held, J Genest Jr; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354(15): 1567–1577 https://doi.org/10.1056/NEJMoa060900 pmid: 16531613
31	X Gao, OI Bermudez, KL Tucker. Plasma C-reactive protein and homocysteine concentrations are related to frequent fruit and vegetable intake in Hispanic and non-Hispanic white elders. J Nutr 2004; 134(4): 913–918 https://doi.org/10.1093/jn/134.4.913 pmid: 15051846
32	WM Broekmans, IA Klöpping-Ketelaars, CR Schuurman, H Verhagen, H van den Berg, FJ Kok, G van Poppel. Fruits and vegetables increase plasma carotenoids and vitamins and decrease homocysteine in humans. J Nutr 2000; 130(6): 1578–1583 https://doi.org/10.1093/jn/130.6.1578 pmid: 10827213
33	C Chrysohoou, DB Panagiotakos, C Pitsavos, A Zeimbekis, A Zampelas, L Papademetriou, C Masoura, C Stefanadis. The associations between smoking, physical activity, dietary habits and plasma homocysteine levels in cardiovascular disease-free people: the ‘ATTICA’ study. Vasc Med 2004; 9(2): 117–123 https://doi.org/10.1191/1358863x04vm542oa pmid: 15521701
34	MA Alomari, OF Khabour, MY Gharaibeh, RA Qhatan. Effect of physical activity on levels of homocysteine, folate, and vitamin B12 in the elderly. Phys Sportsmed 2016; 44(1): 68–73 https://doi.org/10.1080/00913847.2016.1135037 pmid: 26831008
35	R Dankner, A Chetrit, GK Dror, BA Sela. Physical activity is inversely associated with total homocysteine levels, independent of C677T MTHFR genotype and plasma B vitamins. Age (Dordr) 2007; 29(4): 219–227 https://doi.org/10.1007/s11357-007-9041-0 pmid: 19424840
36	MA Albert, RJ Glynn, JE Buring, PM Ridker. Relation between soluble intercellular adhesion molecule-1, homocysteine, and fibrinogen levels and race/ethnicity in women without cardiovascular disease. Am J Cardiol 2007; 99(9): 1246–1251 https://doi.org/10.1016/j.amjcard.2006.12.041 pmid: 17478152
37	PF Jacques, IH Rosenberg, G Rogers, J Selhub, BA Bowman, EW Gunter, JD Wright, CL Johnson. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 1999; 69(3): 482–489 https://doi.org/10.1093/ajcn/69.3.482 pmid: 10075334
38	J Wang, L Zhang, F Wang, L Liu, H; China National Survey of Chronic Kidney Disease Working Group Wang. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens 2014; 27(11): 1355–1361 https://doi.org/10.1093/ajh/hpu053 pmid: 24698853
39	X Qin, J Li, Y Cui, Z Liu, Z Zhao, J Ge, D Guan, J Hu, Y Wang, F Zhang, X Xu, X Wang, X Xu, Y Huo. Effect of folic acid intervention on the change of serum folate level in hypertensive Chinese adults: do methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms affect therapeutic responses? Pharmacogenet Genomics 2012; 22(6): 421–428 https://doi.org/10.1097/FPC.0b013e32834ac5e8 pmid: 21869730
40	L Ma, L Li, Z Tang. Epidemiological characteristics of hyperhomocysteinemia and H-type hypertension in the elderly in Beijing, China. Clin Exp Hypertens 2017; 39(7): 640–644 https://doi.org/10.1080/10641963.2017.1306540 pmid: 28640642
41	Z Chen, F Wang, Y Zheng, Q Zeng, H Liu. H-type hypertension is an important risk factor of carotid atherosclerotic plaques. Clin Exp Hypertens 2016; 38(5): 424–428 https://doi.org/10.3109/10641963.2015.1116547 pmid: 27359263
42	J Li, S Jiang, Y Zhang, G Tang, Y Wang, G Mao, Z Li, X Xu, B Wang, Y Huo. H-type hypertension and risk of stroke in chinese adults: a prospective, nested case-control study. J Transl Int Med 2015; 3(4): 171–178 https://doi.org/10.1515/jtim-2015-0027 pmid: 27847909
43	T Li, X Liu, S Diao, Y Kong, X Duan, S Yang, S Liu, Q Fang, X Cai. H-type hypertension is a risk factor for cerebral small-vessel disease. BioMed Res Int 2020; 2020: 6498903 https://doi.org/10.1155/2020/6498903 pmid: 32090105
44	T Li, J Zhu, Q Fang, X Duan, M Zhang, S Diao, Y Zhou, S Yang, Y Kong, X Cai. Association of H-type hypertension with stroke severity and prognosis. BioMed Res Int 2018; 2018: 8725908 https://doi.org/10.1155/2018/8725908 pmid: 30271787
45	ZH Lu, J Li, XL Li, M Ding, CJ Mao, XY Zhu, CF Liu. Hypertension with hyperhomocysteinemia increases the risk of early cognitive impairment after first-ever ischemic stroke. Eur Neurol 2019; 82(4–6): 75–85 https://doi.org/10.1159/000504704 pmid: 31825940
46	S Hu, L Ren, Y Wang, R Zhang, X Zhao, L Liu, W Li, Y Wang. Homocysteine-lowering therapy and early functional outcomes of ischemic patients with H-type hypertension: a retrospective analysis of CNSR. Australas Phys Eng Sci Med 2015; 38(4): 785–791 https://doi.org/10.1007/s13246-015-0406-x pmid: 26643782
47	M Zhao, X Wang, M He, X Qin, G Tang, Y Huo, J Li, J Fu, X Huang, X Cheng, B Wang, FF Hou, N Sun, Y Cai. Homocysteine and stroke risk: modifying effect of methylenetetrahydrofolate reductase C677T polymorphism and folic acid intervention. Stroke 2017; 48(5): 1183–1190 https://doi.org/10.1161/STROKEAHA.116.015324 pmid: 28360116
48	JD Finkelstein, JJ Martin. Homocysteine. Int J Biochem Cell Biol 2000; 32(4): 385–389 https://doi.org/10.1016/S1357-2725(99)00138-7 pmid: 10762063
49	L Bissoli, V Di Francesco, A Ballarin, R Mandragona, R Trespidi, G Brocco, B Caruso, O Bosello, M Zamboni. Effect of vegetarian diet on homocysteine levels. Ann Nutr Metab 2002; 46(2): 73–79 https://doi.org/10.1159/000057644 pmid: 12011576
50	LJ Appel, ER Miller 3rd, SH Jee, R Stolzenberg-Solomon, PH Lin, T Erlinger, MR Nadeau, J Selhub. Effect of dietary patterns on serum homocysteine: results of a randomized, controlled feeding study. Circulation 2000; 102(8): 852–857 https://doi.org/10.1161/01.CIR.102.8.852 pmid: 10952952

[1]	Qiaoli Shi, Fei Xia, Qixin Wang, Fulong Liao, Qiuyan Guo, Chengchao Xu, Jigang Wang. Discovery and repurposing of artemisinin[J]. Front. Med., 2022, 16(1): 1-9.
[2]	Yu Wang, Lan Li, Yuanjiang Pan, Yu He, Zuhua Chen, Yunhao Xun, Yuhan Xu, Yilei Guo, Jiehong Yang, Jianchun Guo, Haitong Wan. Comparison of the clinical features and therapeutics of COVID-19 in cardio-cerebrovascular disease (CCVD) and non-CCVD patients[J]. Front. Med., 2021, 15(4): 629-637.
[3]	Ling Dai, Xiang Gao, Zhihua Ye, Hanmin Li, Xin Yao, Dingbo Lu, Na Wu. The “Traditional Chinese medicine regulating liver regeneration” treatment plan for reducing mortality of patients with hepatitis B-related liver failure based on real-world clinical data[J]. Front. Med., 2021, 15(3): 495-505.
[4]	Zixin Shu, Yana Zhou, Kai Chang, Jifen Liu, Xiaojun Min, Qing Zhang, Jing Sun, Yajuan Xiong, Qunsheng Zou, Qiguang Zheng, Jinghui Ji, Josiah Poon, Baoyan Liu, Xuezhong Zhou, Xiaodong Li. Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases[J]. Front. Med., 2020, 14(6): 760-775.
[5]	Qingwei Li, Han Wang, Xiuyang Li, Yujiao Zheng, Yu Wei, Pei Zhang, Qiyou Ding, Jiaran Lin, Shuang Tang, Yikun Zhao, Linhua Zhao, Xiaolin Tong. The role played by traditional Chinese medicine in preventing and treating COVID-19 in China[J]. Front. Med., 2020, 14(5): 681-688.
[6]	Zhihang Peng, Wenyu Song, Zhongxing Ding, Quanquan Guan, Xu Yang, Qiaoqiao Xu, Xu Wang, Yankai Xia. Linking key intervention timings to rapid declining effective reproduction number to quantify lessons against COVID-19[J]. Front. Med., 2020, 14(5): 623-629.
[7]	Mengxue Huang, Jingjing Wang, Runshun Zhang, Zhuying Ni, Xiaoying Liu, Wenwen Liu, Weilian Kong, Yao Chen, Tiantian Huang, Guihua Li, Dan Wei, Jianzhong Liu, Xuezhong Zhou. Symptom network topological features predict the effectiveness of herbal treatment for pediatric cough[J]. Front. Med., 2020, 14(3): 357-367.
[8]	Qiqi Zhao, Xin Gao, Guangli Yan, Aihua Zhang, Hui Sun, Ying Han, Wenxiu Li, Liang Liu, Xijun Wang. Chinmedomics facilitated quality-marker discovery of Sijunzi decoction to treat spleen qi deficiency syndrome[J]. Front. Med., 2020, 14(3): 335-356.
[9]	Li Ni, Ling Zhou, Min Zhou, Jianping Zhao, Dao Wen Wang. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19[J]. Front. Med., 2020, 14(2): 210-214.
[10]	Yuan Gao, Zhilei Wang, Jinfa Tang, Xiaoyi Liu, Wei Shi, Nan Qin, Xiaoyan Wang, Yu Pang, Ruisheng Li, Yaming Zhang, Jiabo Wang, Ming Niu, Zhaofang Bai, Xiaohe Xiao. New incompatible pair of TCM: Epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions[J]. Front. Med., 2020, 14(1): 68-80.
[11]	Hudan Pan, Yanfang Zheng, Zhongqiu Liu, Zhongwen Yuan, Rutong Ren, Hua Zhou, Ying Xie, Liang Liu. Deciphering the pharmacological mechanism of Guan-Jie-Kang in treating rat adjuvant-induced arthritis using omics analysis[J]. Front. Med., 2019, 13(5): 564-574.
[12]	Fei Liu, Li Liu, Fang Zheng, Xiangdong Tang, Yongxin Bao, Yunxia Zuo. Identification of surgical patients at high risk of OSAS using the Berlin Questionnaire to detect potential high risk of adverse respiratory events in post anesthesia care unit[J]. Front. Med., 2018, 12(2): 189-195.
[13]	Yufeng Zhao, Bo Liu, Liyun He, Wenjing Bai, Xueyun Yu, Xinyu Cao, Lin Luo, Peijing Rong, Yuxue Zhao, Guozheng Li, Baoyan Liu. A novel classification method for aid decision of traditional Chinese patent medicines for stroke treatment[J]. Front. Med., 2017, 11(3): 432-439.
[14]	Li Ma, Bin Wang, Yuanxiong Long, Hanmin Li. Effect of traditional Chinese medicine combined with Western therapy on primary hepatic carcinoma: a systematic review with meta-analysis[J]. Front. Med., 2017, 11(2): 191-202.
[15]	Xin Du,Daobin Zhou. Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population[J]. Front. Med., 2016, 10(4): 437-443.

Viewed

Full text

Abstract

Cited

Shared

Discussed